4^th European Chemistry Congress

Biography

Biography: Julissa Gonzalez Villegas

Abstract

Surface modification of doxorubicin anticancer drug (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-polyethylene glycol-monophosphate (m-PEG-PO₃) to increase the DOX@ZrP biocompatibility. ³¹P{¹H}MAS NMR data shows a new peak at -26 ppm corresponding to the PO₄^3- groups coordinated with Zr(IV) on the surface. m-PEG-PO₃/Zr(IV)/DOX@ZrP spectra shows no additional resonance centered at d of -22.6 ppm generated by proton-phosphorous cross polarization indicating no partial PEG intercalation in the interlaminar space. Simulated body fluid (SBF) was used to determine the in vitro release of DOX from DOX@ZrP, Zr(IV)/DOX@ZrP, and m-PEG-PO₃/ Zr(IV)/DOX@ZrP.  MTS cell viability assay reveal that m-PEG-PO₃/ Zr(IV)/DOX@ZrP exhibited a 20% increase in the toxicity comparing with free DOX when PC3 cells are exposed for 48 h.  m-PEG-PO₃ polymer coating of DOX@ZrP nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin.